John Coffin

John Coffin, Ph.D.

American Cancer Society Research Professor

Distinguished Professor, Molecular Biology and Microbiology

Tufts University School of Medicine

Dr. Judith Currier

Dr. Currier is Professor of Medicine and Chief of the Division of Infectious Diseases and Co-Director of the Center for AIDS Research and Education Center (CARE) in the Department of Medicine at University of California, Los Angeles (UCLA). Since 2007 she has been Principal Investigator of the UCLA AIDS Prevention and Treatment Clinical Trials Unit. The UCLA CTU includes three sites involved in both prevention and treatment networks in Los Angeles and one in Brazil. In addition, she helps to oversee a large HIV treatment implementation program in Malawi.  She served as Vice Chair of the AIDS Clinical Trials Group Network from 2010-2017 and became Network Chair at the end of 2017.  Her research has focused on HIV Therapeutics, long-term complications of HIV disease with an emphasis on antiretroviral therapy, women’s health and cardiovascular disease.

Daniel R. Kuritzkes, M.D.

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School.  He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center.  Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection.  He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group.  He has served on numerous NIH committees and currently is a member of the NIH Office of AIDS Research Advisory Council.  He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors.  He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases.  His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

Jeff Lifson, M.D.

Dr. Lifson received his M.D. from Northwestern University Medical School in 1982, then pursued residency and research fellowship training in the Department of Pathology at the Stanford University School of Medicine. He became involved in AIDS-related research in 1983, playing a key role in establishing the first program in the United States to try to prevent transfusion-mediated transmission of AIDS through laboratory testing, while also conducting basic in vitro studies of AIDS pathogenesis. After several years of continuing research in AIDS pathogenesis while working in the biotechnology industry, during which time he helped pioneer the development and application of quantitative molecular methods for monitoring HIV replication in infected individuals, Dr. Lifson moved to the Frederick National Laboratory for Cancer Research in 1995, establishing the Retroviral Pathogenesis Section within the AIDS Vaccine Program. His work there has focused on the continuing development and application of quantitative virological and immunological methods for understanding retroviral pathogenesis and evaluating approaches for the prevention and treatment of retroviral infection and AIDS. In 2002, Dr. Lifson was named the director of the AIDS Vaccine Program, which became the AIDS and Cancer Virus Program in 2008. – (ACVP webpage is currently under construction.)